These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 4045267)

  • 21. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined therapy of leprosy in Bhutan.
    Samuel NM; Samuel S
    Indian J Lepr; 1984; 56(3):647-52. PubMed ID: 6549335
    [No Abstract]   [Full Text] [Related]  

  • 23. Non-adherence to leprosy treatment in Western Sudan; the people behind the numbers.
    Coebergh JA; Buddingh H
    Lepr Rev; 2004 Dec; 75(4):404. PubMed ID: 15682977
    [No Abstract]   [Full Text] [Related]  

  • 24. [Leprosy in Haiti].
    Bourée P; Joseph PF; Fils-Aimé F; Morell-Gil RE; Joseph PF
    Sante; 2002; 12(2):281-2. PubMed ID: 12196306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical study of a new sulphonamide RO 4-4393 in leprosy and different infectious skin diseases.
    Dogliotti M
    Panminerva Med; 1965 Dec; 7(12):501-2. PubMed ID: 5858918
    [No Abstract]   [Full Text] [Related]  

  • 26. Patient treatment compliance in leprosy; an unjustifiably critical review.
    Ellard GA
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):117-21. PubMed ID: 7730713
    [No Abstract]   [Full Text] [Related]  

  • 27. A comparative study between 12 and 24-dose therapeutic regimens for multibacillary leprosy patients.
    Sales AM; Sabroza PC; da Costa Nery JA; Duppre NC; Sarno EN
    Int J Lepr Other Mycobact Dis; 2004 Sep; 72(3):320-3. PubMed ID: 15485290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are 18 doses of WHO/MDT sufficient for multibacillary leprosy; results of a trial in Malawi.
    Pönnighaus JM; Boerrigter G
    Int J Lepr Other Mycobact Dis; 1995 Mar; 63(1):1-7. PubMed ID: 7730703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are defaulters with paucibacillary leprosy a problem?
    Jesudasan K; Bradley D; Christian M
    Indian J Lepr; 1985; 57(2):354-9. PubMed ID: 4078362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in epidemiological factors associated with treatment completion status of leprosy patients in the most hyperendemic district of Nepal.
    Kumar RB; Singhasivanon P; Sherchand JB; Mahaisavariya P; Kaewkungwal J; Peerapakorn S; Mahotarn K
    Southeast Asian J Trop Med Public Health; 2004 Jun; 35(2):334-9. PubMed ID: 15691132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
    Pandey A; Uddin MJ; Patel R
    Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study on non-adherence to MDT among leprosy patients.
    Rao PS
    Indian J Lepr; 2008; 80(2):149-54. PubMed ID: 19425509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is it safe to treat the lepromatous patient at home? A study of home exposure to leprosy in Hong Kong.
    Worth RM
    Int J Lepr Other Mycobact Dis; 1968; 36(3):296-302. PubMed ID: 5749656
    [No Abstract]   [Full Text] [Related]  

  • 34. Mass survey of leprosy in Lalitpur district, Nepal.
    Theuvenet WJ; Soares D; Baral JP; Theuvenet-Schutte AR; Palla JP; Jesudasan K; Nakami J; Bista RB; Jayakumar P; Failbus PK
    Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):256-62. PubMed ID: 8046264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An appraisal of medical research in the treatment and control of leprosy.
    Rees RJ
    Lepr India; 1982 Oct; 54(4):783-800. PubMed ID: 6763969
    [No Abstract]   [Full Text] [Related]  

  • 36. Patient compliance with dapsone administration in leprosy.
    Huikeshoven H
    Int J Lepr Other Mycobact Dis; 1981 Jun; 49(2):228-58. PubMed ID: 7024150
    [No Abstract]   [Full Text] [Related]  

  • 37. Serum beta-glucuronidase levels in children with leprosy.
    Nandan D; Venkatesan K; Katoch K; Dayal RS
    Lepr Rev; 2007 Sep; 78(3):243-7. PubMed ID: 18035775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delay in presentation and start of treatment in leprosy patients: a case-control study of disabled and non-disabled patients in three different settings in Ethiopia.
    Bekri W; Gebre S; Mengiste A; Saunderson PR; Zewge S
    Int J Lepr Other Mycobact Dis; 1998 Mar; 66(1):1-9. PubMed ID: 9614833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Leprosy in Tunisia].
    Jomaa B
    Acta Leprol; 1986; 4(2):141-53. PubMed ID: 3551446
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.